Table 5 Studies on treatment with interferon-α for prevention of HCC in patients with HCV-related cirrhosis

Mazzella, 1996 [184]

Italy

NRCT, P

3 MU tiw (52)

32 (12–71)

T 193

C 91

T: 5/193 (2.6%)

C: 9/91 (9.9%)

Significant

Fattovich, 1997 [196]

Europe

NRCT, P

≥ 200 MU

60 (1–153)

T 193

C 136

T: 7/193 (3.6%)

C: 16/136 (11.8%)

Not significant

Bruno, 1997 [45]

Italy

NRCT, P

6 MU tiw (26)

68 (60–84)

T 82

C 81

T: 6/82 (7.3%)

C: 14/81 (17.3%)

Not significant

Serfaty, 1998 [197]

France

NRCT, P

3 MU tiw (48)

40 (6–72)

T 59

C 44

T: 2/59 (3.4%)

C: 9/44 (20.1%)

Significant

IHCSG, 1998 [187]

Argentina, Germany, Italy, Saudi Arabia

NRCT, R

9–30 MU/wk (3–30 months)

(36–250)

T 232

C 259

T: 2/232 (0.9%)

C: 48/259 (18.5%)

Significant

Imai, 1998 [198]

Japan

NRCT, R

480 MU (26)

48 (3–65)

T 32

C 20

T: 8/32 (25%)

C: 7/20 (35%)

Significant

Benvegnù, 1998 [188]

Italy

NRCT, P

3–6 MU tiw (26–52)

72

T 75

C 77

T: 4/75 (5.3%)

C: 20/77 (26.0%)

Significant

Valla, 1999 [199]

France

RCT

3 MU TIW (48)

40 (37–53)

T 47

C 52

T: 5/47 (10.6%)

C: 9/52 (17.3%)

Not significant

Yoshida, 1999 [194]

Japan

NRCT, R

480 MU (23)

52

T 230

C 107

T: 33/230 (14.3%)

C: 29/107 (27.1%)

NR

Okanoue, 1999 [200]

Japan

NRCT, R

3–10 MU qd or tiw (16–24)

1–7 years

T 40

C 55

T: 7/40 (17.5%)

C: 22/55 (40.0%)

NR

Nishiguchi, 1995/2001 [201,202]

Japan

RCT

6 MU tiw (12–24)

104 (31–110)

T 45

C 45

T: 12/45 (26.7%)

C: 33/45 (73.3%)

Significant

Gramenzi, 2001 [203]

Italy

RCT, P

741 MU

72

T 72

C 72

T: 6/72 (8.3%)

C: 19/72 (26.4%)

Significant

Testino, 2002 [204]

Italy

RCT

3 MU tiw (52)

96.5 ± 18

T 51

C 71

T: 15.51 (29.4%)

C: 24/71 (33.8%)

Not significant